Business Context and Reporting Period
Company: Aziyo Biologics, Inc. (Note: Request metadata listed "Elutia Inc." but the filing is for Aziyo Biologics, Inc.)
Filing Type: Form 8-K (Current Report)
Date of Report: August 14, 2023
Reporting Period: Second quarter ended June 30, 2023
Business Context: The filing serves as a notification that the Company issued a press release announcing its financial results for the second quarter of 2023. The press release is included as Exhibit 99.1.
Key Financial Metrics
The provided text is a cover sheet and does not contain specific financial data. It references a press release (Exhibit 99.1) for details on revenue, profit, cash flow, margins, debt, and liquidity. Consequently, the filing text does not provide a clear value for any specific financial metric.
Material Changes
No material changes or comparative financial data are disclosed within the text of this Form 8-K. The document solely announces the availability of the Q2 2023 results.
Guidance, Outlook, and Risks
Management Commentary: The filing states that the Company issued a press release regarding Q2 2023 results but does not summarize the content of that commentary.
Legal Disclaimer: The information in Item 2.02 and Exhibit 99.1 is not deemed "filed" under Section 18 of the Exchange Act and is not incorporated by reference into other filings unless expressly stated.
Emerging Growth Company: The registrant is identified as an emerging growth company.
Investor Verification Checklist
- Review Exhibit 99.1 (Press Release dated August 14, 2023) for actual Q2 2023 financial figures.
- Verify the discrepancy between the request metadata ("Elutia Inc.") and the filing registrant ("Aziyo Biologics, Inc.").
- Check the Company's status as an emerging growth company for potential differences in financial reporting standards.
- Confirm if the press release contains updated guidance or material risk factors not summarized in this 8-K.